the challenges of treating tp53-mutated aml and mds
Published 1 year ago • 792 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
3:39
the association between prior exposure to lenalidomide and tp53-mutated aml/mds
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:50
magrolimab in tp53 mutated aml and mds
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
8:14
progress in the treatment of tp53 mutated aml
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
5:54
what testing should be done to confirm an mds diagnosis? #mds
-
5:45
pathogenic tp53 mutations associated with poor prognosis in pediatric aml
-
7:37
magrolimab in tp53-mutated aml and mds: what are the latest updates from eha2022?
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
2:42
challenges in treating patients with tp53-mutated mcl & promising novel therapies being explored
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
3:11
challenges in treating tp53-mutated aml, hope on the horizon
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
1:25
should patients with tp53-mutated mds receive stem cell transplant?
-
1:13
targeting p53 in mds